Advances in immunotyping of colorectal cancer

Yinhang Wu; Yinhang Wu; Yinhang Wu; Jing Zhuang; Jing Zhuang; Jing Zhuang; Zhanbo Qu; Zhanbo Qu; Zhanbo Qu; Xi Yang; Xi Yang; Xi Yang; Shuwen Han; Shuwen Han; Shuwen Han

doi:10.3389/fimmu.2023.1259461

Frontiers in Immunology (Oct 2023)

Advances in immunotyping of colorectal cancer

Yinhang Wu,
Yinhang Wu,
Yinhang Wu,
Jing Zhuang,
Jing Zhuang,
Jing Zhuang,
Zhanbo Qu,
Zhanbo Qu,
Zhanbo Qu,
Xi Yang,
Xi Yang,
Xi Yang,
Shuwen Han,
Shuwen Han,
Shuwen Han

Affiliations

Yinhang Wu: Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, China
Yinhang Wu: Key Laboratory of Multiomics Research and Clinical Transformation of Digestive Cancer of Huzhou, Huzhou, China
Yinhang Wu: Huzhou Central Hospital, Fifth Affiliated Clinical Medical College of Zhejiang Chinese Medical University, Huzhou, China
Jing Zhuang: Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, China
Jing Zhuang: Key Laboratory of Multiomics Research and Clinical Transformation of Digestive Cancer of Huzhou, Huzhou, China
Jing Zhuang: Huzhou Central Hospital, Fifth Affiliated Clinical Medical College of Zhejiang Chinese Medical University, Huzhou, China
Zhanbo Qu: Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, China
Zhanbo Qu: Key Laboratory of Multiomics Research and Clinical Transformation of Digestive Cancer of Huzhou, Huzhou, China
Zhanbo Qu: Huzhou Central Hospital, Fifth Affiliated Clinical Medical College of Zhejiang Chinese Medical University, Huzhou, China
Xi Yang: Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, China
Xi Yang: Key Laboratory of Multiomics Research and Clinical Transformation of Digestive Cancer of Huzhou, Huzhou, China
Xi Yang: Huzhou Central Hospital, Fifth Affiliated Clinical Medical College of Zhejiang Chinese Medical University, Huzhou, China
Shuwen Han: Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, China
Shuwen Han: Key Laboratory of Multiomics Research and Clinical Transformation of Digestive Cancer of Huzhou, Huzhou, China
Shuwen Han: Huzhou Central Hospital, Fifth Affiliated Clinical Medical College of Zhejiang Chinese Medical University, Huzhou, China

DOI: https://doi.org/10.3389/fimmu.2023.1259461
Journal volume & issue: Vol. 14

Abstract

Read online

Immunotherapy has transformed treatment for various types of malignancy. However, the benefit of immunotherapy is limited to a minority of patients with mismatch-repair-deficient (dMMR) and microsatellite instability-high (MSI-H) (dMMR-MSI-H) colorectal cancer (CRC). Understanding the complexity and heterogeneity of the tumor immune microenvironment (TIME) and identifying immune-related CRC subtypes will improve antitumor immunotherapy. Here, we review the current status of immunotherapy and typing schemes for CRC. Immune subtypes have been identified based on TIME and prognostic gene signatures that can both partially explain clinical responses to immune checkpoint inhibitors and the prognosis of patients with CRC. Identifying immune subtypes will improve understanding of complex CRC tumor heterogeneity and refine current immunotherapeutic strategies.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords